Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kadmus Pharmaceuticals Inc.

Latest From Kadmus Pharmaceuticals Inc.

Cannasat Therapeutics Inc.

Admit it, you inhaled. It's comments like that that greet David Hill, co-founder and CEO of Cannasat Therapeutics, a Toronto-based company seeking to exploit cannabinoid receptor-targeting drugs including THC (delta-9-tetrahydrocannabinol), the psychoactive component in marijuana (cannabis). However, the laughing ceases once he starts talking about the evidence of the effectiveness of cannabis-derived compounds in treating the symptoms associated with such conditions such as pain, multiple sclerosis, HIV/AIDS, cancer, mood disorders, glaucoma, and many others.

BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register